

Development of an AI-Based PD1-IL18v Bispecific candidate with immune cell-specific activity in the tumor microenvironment.

Galux Inc.
Galux

ONCOLOGY

Candidate

Product Type	rProtein
Indication	Patients with primary or acquired resistance to PD-1 inhibitors
Target	Interleukin-18(IL-18), IL-18 Receptors(IL-18R α ;CD218a, IL-18R β ;CD218b) and PD-1
MoA(Mechanism of Action)	1. Does not bind to IL-18 BP 2. Attenuates receptor-binding affinity to minimize adverse effects and improve pharmacokinetics, while preserving appropriate therapeutic signaling 3. Forms a bispecific Ab via anti-PD-1 conjugation, enabling synergistic cis-targeting
Competitiveness	1. GALUX proprietary AI-designed IL-18 variant — Successfully AI-designed through GALUX's proprietary AI design platform to evade IL-18BP binding, modulate receptor engagement, and improve stability 2. Decoy-resistant IL-18 variant — AI-designed IL-18 that bypasses IL-18BP-mediated inhibition and maintains activity in the tumor microenvironment. 3. Modulated IL-18R binding — Reduces systemic/non-specific receptor engagement to improve safety, therapeutic window, and tumor accumulation
Development Stage	Lead
Route of Administration	IV/SC

Any unauthorized distribution or reproduction of this material is strictly prohibited.